Multidrug resistance in haematological malignancies

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Refractory disease in acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), and multiple myeloma (MM) is often linked to multidrug resistance (MDR) gene expression.
• Specific MDR genes, including MDR1, MRP1, and LRP, are recognized as significant adverse prognostic indicators in AML, T-cell ALL (T-ALL), and MM.
• Recent advancements allow for the reversal of clinical multidrug resistance by inhibiting P-glycoprotein-mediated drug efflux.

Purpose of the Study:

• To discuss the role of multidrug resistance genes in the development of refractory leukaemias and multiple myeloma.
• To explore the potential of P-glycoprotein efflux blockers as therapeutic agents for overcoming clinical multidrug resistance.
• To review novel therapeutic approaches for treating refractory haematological malignancies.

Main Methods:

• Literature review and analysis of existing research on multidrug resistance in leukaemias and myeloma.
• Discussion of the mechanisms of P-glycoprotein-mediated drug efflux.
• Evaluation of the clinical relevance of MDR reversal agents.

Main Results:

• Expression of MDR genes (MDR1, MRP1, LRP) is a key factor in treatment refractoriness for AML, ALL, and MM.
• Inhibition of P-glycoprotein-mediated efflux shows promise in reversing multidrug resistance.
• Emerging strategies focus on targeting MDR to improve treatment outcomes.

Conclusions:

• Targeting MDR offers a promising avenue for treating refractory leukaemias and multiple myeloma.
• Further research into MDR reversal agents is crucial for developing effective therapies.
• Understanding MDR mechanisms is vital for improving patient prognosis in haematological malignancies.